Severe Rh alloimmunization and hemolytic disease of the fetus managed with plasmapheresis, intravenous immunoglobulin and intrauterine transfusion: A case report

Brett L. Houston, Rachelle Govia,Ahmed M. Abou-Setta,Gregory J. Reid,Marie Hadfield, Chantalle Menard, Jocelyn Noyd, Susan Main,Ryan Zarychanski

Transfusion and Apheresis Science(2015)

引用 19|浏览7
暂无评分
摘要
Rh alloimmunization remains a potentially devastating complication of pregnancy, with fetal anemia causing hydrops and intrauterine death. Intrauterine transfusion is the standard treatment, but is particularly dangerous before 20 weeks gestation. When the need for intrauterine transfusion is anticipated early in pregnancy, immune-modulating therapies such as plasmapheresis and IVIG have been used to delay transfusion to a later gestational age. We report a 35-year-old G5P1 Rh(D)-negative woman with severe Rh alloimmunization managed successfully with sequential plasmapheresis, intravenous immune globulin and intrauterine transfusion. The optimal plasmapheresis treatment protocol and incremental benefit of IVIG remains unknown.
更多
查看译文
关键词
Alloimmunization,Hemolytic disease of the fetus and newborn,Plasmapheresis,Intravenous immune globulin,Pregnancy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要